Gilead shows high cure rates for hepatitis C combo drug
This article was originally published in Scrip
Executive Summary
Gilead Sciences said its once-daily combination drug showed high cure rates in hepatitis C patients in late-stage studies, results that will help the company make a case for approval early next year.